Biotech ETFs To Buy As Cancer Drug Breakthroughs Accelerate

Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of precision oncology.

Looking ahead, the broader market opportunity remains substantial, with the global oncology drugs market projected to grow from $256.5 billion in 2025 to almost $700 billion by 2034, representing an 11.8% CAGR (as predicted by Fortune Business Insights).

For equity market investors, this growth projection represents an opportune moment to add biotech exchange-traded funds (ETFs) to their portfolios.

This post originally appeared at Zacks.